MedPharm’s expertise in vaginal drug delivery supports the development of safe, effective, and patient-centric therapies that meet the unique physiological and regulatory requirements of mucosal administration. Whether you’re developing treatments for infectious diseases, hormonal imbalance, contraception, or systemic delivery via the vaginal route, MedPharm delivers proven strategies that move your product forward with confidence.
The vaginal route offers direct access to local tissue, a large surface area for absorption, and the potential to bypass first-pass metabolism—making it an ideal pathway for both local and systemic therapeutic delivery. However, formulating for this route requires deep understanding of:
Vaginal pH variability
Mucosal permeability and retention
Patient comfort and compliance
Microbiota sensitivity
Regulatory and device compatibility considerations
MedPharm brings this specialized knowledge to every vaginal drug development program we support.
Our team develops and optimizes a wide range of vaginal dosage forms, including:
Gels and creams for localized or systemic absorption
Vaginal rings with sustained-release properties
Suppositories and ovules for targeted delivery
Foams and films for ease of use and rapid distribution
Mucoadhesive formulations to enhance retention and effectiveness
Each formulation is carefully tailored to address your molecule’s characteristics, therapeutic goals, and patient population.
To accelerate your development program and meet regulatory expectations, MedPharm provides:
In vitro release and permeation testing using vaginal tissue models
Compatibility testing with common applicators and devices
Microbial limit and stability testing under ICH conditions
Mucoadhesion and rheology profiling to assess product performance
Histological and morphological assessments of tissue integrity
MedPharm’s integrated approach supports a seamless transition from lab to clinic. We ensure your vaginal drug product meets global regulatory expectations with:
Customized CMC packages for IND, NDA, and 505(b)(2) submissions
Clinical trial material (CTM) manufacturing in scalable formats
QP-reviewed documentation for European submissions
Strategy alignment for labeling, shelf life, and packaging
With decades of experience in mucosal delivery and topical formulation science, MedPharm is uniquely positioned to help clients develop differentiated vaginal therapies that are safe, effective, and commercially viable. Whether you are entering preclinical development or preparing for late-stage clinical trials, our team provides the scientific rigor and regulatory insight your program demands.
Lorem